Journal of Pharmacy and PharmaceuticsJournal of Pharmacy and PharmaceuticsJournal of Pharmacy and PharmaceuticsJournal of Pharmacy and Pharmaceutics2576-3091Ommega Online PublishersNew Jersey, USA195310.15436/2377-1313.18.1953Research ArticleSome Aspects of Medicine Distribution in SudanSome Aspects of Medicine Distribution in SudanAbdeen Mustafa OmerOccupational Health Administration Ministry of Health Khartoum SudanEditor* E-mail: abdeenomer2@yahoo.co.uk
The authors have declared that no competing interests exist.
20181009201852JPP-18-RA-195326082018040920182018Creative Commons Attribution LicenseThis is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. nbsp The strategy of price liberalisation and privatisation had been implemented in Sudan over the last decade and has had a positive result on government deficit The investment law approved recently has good statements and rules on the above strategy in particular to pharmacy regulations Under the pressure of the new privatisation policy the government introduced radical changes in the pharmacy regulations To improve the effectiveness of the public pharmacy resources should be switched towards areas of need reducing inequalities and promoting better health conditions Medicines are financed either through cost sharing or full private The role of the private services is significant A review of reform of financing medicines in Sudan is given in this study Also it highlights the current drug supply system in the public sector which is currently responsibility of the Central Medical Supplies Public Corporation CMS In Sudan the researchers did not identify any rigorous evaluations or quantitative studies about the impact of drug regulations on the quality of medicines and how to protect public health against counterfeit or low quality medicines although it is practically possible However the regulations must be continually evaluated to ensure the public health is protected against by marketing high quality medicines rather than commercial interests and the drug companies are held accountable for their conduct 10